Commentary

SGLT-2 inhibitors in heart failure: Time for broader eligibility and earlier initiation

Enrico G. Ferro, MD, Bertram Pitt, MD and Deepak L. Bhatt, MD, MPH
Cleveland Clinic Journal of Medicine November 2021, 88 (11) 601-606; DOI: https://doi.org/10.3949/ccjm.88a.21045

Article Information

vol. 88 no. 11 601-606
DOI 
https://doi.org/10.3949/ccjm.88a.21045
PubMed 
34728485
Published By 
Cleveland Clinic Journal of Medicine
Print ISSN 
0891-1150
Online ISSN 
1939-2869
History 
  • Published online November 2, 2021.
Copyright & Usage 
Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.

Author Information

  1. Enrico G. Ferro, MD
  1. Department of Medicine, Brigham and Women’s Hospital, Boston, MA; Harvard Medical School, Boston, MA
  1. Bertram Pitt, MD
  1. University of Michigan, Ann Arbor, MI, Emeritus Professor of Medicine, University of Michigan School of Medicine, Ann Arbor, MI; Co-Chair, SOLOIST trial
  1. Deepak L. Bhatt, MD, MPH⇑
  1. Professor of Medicine, Harvard Medical School, Boston, MA, Executive Director of Interventional Cardiovascular Programs, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, MA; Chair, SOLOIST and SCORED trials
  1. Address:
    Deepak L. Bhatt, MD, MPH, Professor of Medicine, Harvard Medical School, 75 Francis Street, Boston, MA 02115; DLBhattMD{at}post.Harvard.edu

Cited By...

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects